Vutrisiran + Sterile Normal Saline (0.9% NaCl)

Phase 3Active

1 views this week 0 watching⚡ Active

Interest: 41/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

Conditions

Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

Trial Timeline

Nov 26, 2019 → Dec 2, 2026

NCT ID

NCT04153149

About Vutrisiran + Sterile Normal Saline (0.9% NaCl)

Vutrisiran + Sterile Normal Saline (0.9% NaCl) is a phase 3 stage product being developed by Alnylam Pharmaceuticals for Transthyretin Amyloidosis (ATTR) With Cardiomyopathy. The current trial status is active. This product is registered under clinical trial identifier NCT04153149. Target conditions include Transthyretin Amyloidosis (ATTR) With Cardiomyopathy.

What happened to similar drugs?

3 of 18 similar drugs in Transthyretin Amyloidosis (ATTR) With Cardiomyopathy were approved

Approved (3) Terminated (0) Active (15)

🔄Eplontersen + PlaceboAstraZenecaPhase 3

🔄EplontersenAstraZenecaPhase 3

🔄Eplontersen + PlaceboAstraZenecaPhase 3

🔄NNC6019-0001 + Placebo (NNC6019-0001)Novo NordiskPhase 3

✅tafamidis megluminePfizerApproved

🔄TafamidisPfizerPhase 3

🔄tafamidisPfizerPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04153149	Phase 3	Active	Nov 26, 2019	Dec 2, 2026	Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

Competing Products

20 competing products in Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

See all competitors

Product	Company	Stage	Hype Score
Eplontersen Solution for Injection	AstraZeneca	Phase 1	29
Eplontersen + Placebo	AstraZeneca	Phase 3	44
Treatment of transthyretin (ATTR) amyloidosis in observational study setting	AstraZeneca	Pre-clinical	33
Eplontersen	AstraZeneca	Phase 3	47
Eplontersen + Placebo	AstraZeneca	Phase 3	44
NNC6019-0001 + Placebo (NNC6019-0001)	Novo Nordisk	Phase 3	47
NNC6019-0001	Novo Nordisk	Phase 2	39
NNC6019-0001 + Placebo (NNC6019-0001)	Novo Nordisk	Phase 2	35
Coramitug	Novo Nordisk	Phase 1	36
Tafamidis	Pfizer	Pre-clinical	26
Tafamidis	Pfizer	Pre-clinical	30
tafamidis meglumine	Pfizer	Approved	43
Fx-1006A	Pfizer	Phase 2	35
Tafamidis	Pfizer	Phase 3	40
Tafamidis 61 milligrams	Pfizer	Pre-clinical	26
Treatment for TTR amyloidosis + Treatment for TTR amyloidosis	Pfizer	Pre-clinical	26
Vyndaqel	Pfizer	Pre-clinical	26
tafamidis	Pfizer	Phase 3	40
Tafamidis	Pfizer	Approved	43
Tafamidis	Pfizer	Pre-clinical	26